Published • loading... • Updated
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
- Antengene will present preclinical results from its costimulatory T cell engager platform at the 2026 Society for Immunotherapy of Cancer Annual Meeting.
- The meeting will take place from November 4 to 8, 2026, at the Phoenix Convention Center in Phoenix, Arizona.
- The presentation will cover a CD2-based platform combining a CD3γε/δε-targeting antibody with CD3 masking.
- Bing Hou will present the abstract during a Rapid Oral session on November 6, 2026.
Insights by Ground AI
40 Articles
40 Articles
Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies,…
·Pennsylvania, United States
Read Full ArticleCoverage Details
Total News Sources40
Leaning Left5Leaning Right5Center23Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
15%
C 70%
15%
Factuality
To view factuality data please Upgrade to Premium
